The present composition provides for mitigating adverse effects of alcohol consumption. The composition includes a fructose source comprising between 5% and 75% of a total weight of the composition, a niacinamide source comprising between 0.1% and 1% of the total weight, and a glycoprotein source comprising between 0.1% and 2% of the total weight, wherein the total weight is a weight prior to inclusion with a hydrating source. The composition can be disposed in a powder or dissolved form, as part of a concentrate, and/or part of a beverage. The composition can include mixability for diluting or mixing with the liquid or beverage for user consumption and absorprtion.

The present composition provides for mitigating adverse effects of alcohol consumption. The composition includes a fructose source comprising between 5% and 75% of a total weight of the composition, a niacinamide source comprising between 0.1% and 1% of the total weight, and a glycoprotein source comprising between 0.1% and 2% of the total weight, wherein the total weight is a weight prior to inclusion with a hydrating source. The composition can be disposed in a powder or dissolved form, as part of a concentrate, and/or part of a beverage. The composition can include mixability for diluting or mixing with the liquid or beverage for user consumption and absorprtion.

The food additive includes the following components in weight percent: liquorice—Glycyrrhiza glabra from 1.19% to 47.61%, sweet wormwood—Artemisia annua from 1.19% to 47.61%, quinine bark extract—Cinho from 1.19% to 47.61%, hawthorn extract—Crataegus from 1.19% to 47.61%, dandelion extract—Taraxcum from 1.19% to 47.61%, vitamin C—Ascorbic acid from 1.19% up to 47.61%, DD-Galacturonic acid from 1.19% to 47.61%, apple pectin from 1.19% to 47.61%, bitter orange—Citrus aurantium from 1.19% to 47.61%, ginger—Zingiber officinale from 0.23% to 11.9%, Radix isatidis from 0.23% to 11.9%, Lindera aggregate—0.23% to 11.9%, woad—Isatis indigotica from 0.23% to 9.52%, Torreya nucifera from 0.23% to 9.52%, geranium extract—Pelargonium from 0.23% to 9.52%, Zinc from 0.23% to 2.38% and Sodium Selenite from 0.00119% to 0.04762%.

The food additive includes the following components in weight percent: liquorice—Glycyrrhiza glabra from 1.19% to 47.61%, sweet wormwood—Artemisia annua from 1.19% to 47.61%, quinine bark extract—Cinho from 1.19% to 47.61%, hawthorn extract—Crataegus from 1.19% to 47.61%, dandelion extract—Taraxcum from 1.19% to 47.61%, vitamin C—Ascorbic acid from 1.19% up to 47.61%, DD-Galacturonic acid from 1.19% to 47.61%, apple pectin from 1.19% to 47.61%, bitter orange—Citrus aurantium from 1.19% to 47.61%, ginger—Zingiber officinale from 0.23% to 11.9%, Radix isatidis from 0.23% to 11.9%, Lindera aggregate—0.23% to 11.9%, woad—Isatis indigotica from 0.23% to 9.52%, Torreya nucifera from 0.23% to 9.52%, geranium extract—Pelargonium from 0.23% to 9.52%, Zinc from 0.23% to 2.38% and Sodium Selenite from 0.00119% to 0.04762%.

The present invention relates to anti-cancer agents comprising 1,2,4-trioxane compounds and anti-cancer agents comprising combinations comprising 1,2,4-trioxane compounds and chlorogenic acids. The invention further provides pharmaceutical compositions comprising such anti-cancer agents, kits comprising the same as well as methods and treatment regimens of using the aforementioned anti-cancer agents, pharmaceutical compositions and kits in the treatment and prevention of cancer and for prolonging survival of subjects having cancer, in particular ovarian cancer or lung cancer.

The present invention relates to anti-cancer agents comprising 1,2,4-trioxane compounds and anti-cancer agents comprising combinations comprising 1,2,4-trioxane compounds and chlorogenic acids. The invention further provides pharmaceutical compositions comprising such anti-cancer agents, kits comprising the same as well as methods and treatment regimens of using the aforementioned anti-cancer agents, pharmaceutical compositions and kits in the treatment and prevention of cancer and for prolonging survival of subjects having cancer, in particular ovarian cancer or lung cancer.

The present invention relates to anti-cancer agents comprising 1,2,4-trioxane compounds and anti-cancer agents comprising combinations comprising 1,2,4-trioxane compounds and chlorogenic acids. The invention further provides pharmaceutical compositions comprising such anti-cancer agents, kits comprising the same as well as methods and treatment regimens of using the aforementioned anti-cancer agents, pharmaceutical compositions and kits in the treatment and prevention of cancer and for prolonging survival of subjects having cancer, in particular ovarian cancer or lung cancer.

Compositions and methods are presented that help reduce cellular ageing, improve cellular stress resilience, and/or promote increased longevity. Especially preferred compositions include a combination of a purine alkaloid, an isothiocyanate or thioglucoside, and a metal-containing antioxidant, where the purine alkaloid, the isothiocyanate or thioglucoside, and the metal-containing antioxidant may be chemically isolated compounds or extracts or other preparations from naturally occurring entities such as plants, bacteria, yeast, etc. Advantageously, contemplated compositions will be effective to reduce and repair oxidative stress, improve mitochondrial function, augment DNA repair and telomere maintenance, increase fatty acid metabolism, and modulate histone deacetylation.

Compositions and methods are presented that help reduce cellular ageing, improve cellular stress resilience, and/or promote increased longevity. Especially preferred compositions include a combination of a purine alkaloid, an isothiocyanate or thioglucoside, and a metal-containing antioxidant, where the purine alkaloid, the isothiocyanate or thioglucoside, and the metal-containing antioxidant may be chemically isolated compounds or extracts or other preparations from naturally occurring entities such as plants, bacteria, yeast, etc. Advantageously, contemplated compositions will be effective to reduce and repair oxidative stress, improve mitochondrial function, augment DNA repair and telomere maintenance, increase fatty acid metabolism, and modulate histone deacetylation.

Provided is a method for extracting and refining alkaloids from ipecac, comprising: (1) grinding ipecac, adding acidic methanol/ethanol solution for extraction, obtaining an extraction solution A, concentrating under a reduced pressure, and obtaining a concentrated solution B; (2) using reversed-phase polymer filler J for adsorption, and performing desorption by washing with water, collecting a washing solution C, eluting with an alcoholic solution E and collecting a desorption solution D; (3) injecting the washing solution C and the desorption solution D into a preparative high performance liquid chromatograph for separation and purification respectively, to collect a solution G, and a solution H and a solution I respectively; and (4) concentrating the solutions G, H and I, which are then subjected to reversed-phase polymer filler K for adsorption respectively; eluting them respectively after adsorption with an alcoholic solution F; concentrating obtained eluates to dryness; and then performing vacuum drying.